Can You Change from Mounjaro to Ozempic for Weight Loss?

Step 1: Understand what Ozempic is licensed for before considering any switch

Ozempic is a brand of semaglutide made by Novo Nordisk, and it is a well-established medicine, but its UK licence covers type 2 diabetes, full stop. The NHS medicines page for semaglutide makes this clear: Ozempic is not approved by the MHRA for weight management, and prescribing it for that purpose would be off-label in a way UK regulators have specifically flagged. If someone has offered you Ozempic for weight loss without a diabetes diagnosis, that is a prompt to question whether the supply chain is legitimate.

The semaglutide product that is licensed for weight loss is Wegovy, which uses a higher maintenance dose (up to 2.4mg weekly, with a 7.2mg pen now also MHRA-approved) and sits within a different clinical programme. The two brands are not interchangeable at the pharmacy counter, regardless of the fact they share an active ingredient.

So the direct answer to whether you can change from Mounjaro to Ozempic for weight loss is: no, not through any regulated UK route. What you can explore with a prescriber is whether moving from tirzepatide to Wegovy makes sense for you, and if you are curious about whether Mounjaro is itself a semaglutide drug, that question is worth clearing up before comparing options.

Step 2: Compare what Mounjaro and Wegovy actually do differently

Both medicines slow gastric emptying and reduce appetite, but they work on different receptors. Mounjaro activates both GIP and GLP-1 receptors, the only dual-agonist weight-loss medicine currently licensed in the UK. Wegovy targets GLP-1 receptors only. That distinction shows up in the trial data: in SURMOUNT-1, tirzepatide produced an average body-weight reduction of around 20–21% at the 15mg dose over 72 weeks, while the STEP 1 trial reported around 15% for semaglutide 2.4mg over 68 weeks. Head-to-head, the SURMOUNT-5 trial published in the New England Journal of Medicine (2025) found tirzepatide produced greater average weight loss than semaglutide 2.4mg in adults with obesity and no diabetes.

That said, individual responses vary considerably. Some people tolerate one medicine better than the other; GI side effects (nausea, loose stools, reflux) can differ in intensity between the two. The gap may also narrow as the 7.2mg Wegovy pen, approved by the MHRA in April 2026, becomes more established in practice.

*NICE TA875 recommends Wegovy for up to two years within a specialist weight management service; TA1026 applies to tirzepatide in the NHS phased rollout. Private eligibility differs. Sources: NICE TA1026; NICE TA875.

Step 3: What a switch from Mounjaro to Wegovy actually involves

If you are currently on Mounjaro and want to explore Wegovy, the process starts with a clinical review. There is no standard washout period published in the SmPCs, but a prescriber will look at your current dose, how long you have been on it, your tolerability history, and your reasons for wanting to change. People sometimes raise this question mid-titration when they hear about a friend's experience with semaglutide, or when a supply issue crops up, both valid reasons to have the conversation.

A good time to raise it is at your repeat review rather than mid-pen, partly for continuity and partly because a prescriber can document your baseline properly. At nume, every repeat order goes back to a prescriber's desk for fresh sign-off, which also means every repeat is a natural point to discuss a switch. If you want to read more about how that process works in practice, our guide to switching from Mounjaro to Wegovy covers the steps in detail. You can also check the broader comparison of the two treatments on our Wegovy versus Mounjaro page.

One practical note: if you are ordering before the midday cut-off on a weekday and your switch has been approved, the new pen ships the same day. That rhythm matters if you are trying to avoid a gap in treatment.

The clinical decision: which medicine fits you is not a search-engine answer

Reviewing the evidence, Mounjaro has produced larger average weight reductions in trials, and the SURMOUNT-5 head-to-head supports that picture. But averages are not individual outcomes. Some people do better on semaglutide; some find Mounjaro's GI side effects harder to manage at higher doses; some have a clinical history that makes one medicine more appropriate than the other. The right medicine is the one that works safely for you, at a dose your system tolerates, prescribed by someone who knows your full picture.

Ozempic does not enter that calculation for weight loss, it simply is not a licensed option in this context. If you are looking at semaglutide-based treatment, Wegovy is the correct product, and if you have also come across Zepbound and wondered whether Zepbound is a semaglutide, that is a reasonable question given how often the drug classes get conflated. Any switch from tirzepatide to semaglutide warrants a proper prescriber review rather than a self-directed change. Our clinical team carries out exactly that kind of review. For a broader look at the options available, the weight-loss treatment overview is a useful starting point, and our FAQs answer several of the questions that come up around switching. Which treatment suits you is a clinical decision our prescribers make with you.

Speak to our prescribers about whether your current treatment is still the right fit, or whether a switch is worth exploring.